Faron appoints new CTO to strengthen late-stage development activities

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi as the Company’s Chief Technical Officer (CTO).

Heikki Jouttijärvi brings decades of experience in biopharma manufacturing, supply chain management and commercial operations. Most recently, he has been the SVP of Commercial Business Operations at Adverum Biotechnologies, Inc that was acquired by Eli Lilly. Prior to that Mr. Jouttijärvi has held various global roles at Menlo Therapeutics, Inc and Santen Pharmaceutical Company, Ltd. He holds a M.Sc degree in Pharmacy from the University of Helsinki.

“We are extremely happy to welcome Heikki as a part of the Faron team. His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced Phase IIb trial in HR MDS”, comments Dr. Juho Jalkanen, CEO of Faron.

“I am honored to join the Faron team at this exciting point in time in the development of bexmarilimab. I have been amazed by the resilience and excellent hard work done with bexmarilimab to date and I am humbled to be able to join the program at this stage. We look forward to advance the program to the benefit patients, whom deserve our ultimate commitment”, says Mr. Jouttijärvi, newly appointed CTO of Faron Pharmaceuticals.